News Release

<< Back

SurModics Reports Second Quarter Results; Record Revenue; Record Profit Excluding One-Time Charge

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--April 20, 2005--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today reported financial results for the second quarter ended March 31, 2005.

Second Quarter Highlights:
--------------------------

  • Record revenue of $15.7 million

  • Including one-time, non-cash in-process R&D charge of $30.3 million related to the acquisition of InnoRx:

    • Operating loss of $21.1 million

    • Net loss of $24.4 million

    • Diluted EPS of ($1.34)


  • Excluding the charge:
    • Record operating income of $9.1 million; operating margin of 58%

    • Record net income of $5.9 million

    • Diluted EPS of $.32


  • Fourth consecutive quarter with non-Cordis revenue exceeding Cordis revenue

  • Six new licenses signed; two new customer products introduced

"SurModics is pleased to report record revenue and net income, excluding the one-time charge, for the second quarter," said Dale Olseth, Chairman and CEO. "This marks our third straight quarter of record revenue. We are proud of the progress we have achieved across our six business units."

Revenue for the second quarter of fiscal 2005 was a record $15.7 million, an increase of 23% from $12.7 million in the second quarter of fiscal 2004. During the quarter, the company recorded a $30.3 million charge for in-process research and development (IPR&D) in connection with its acquisition of InnoRx, Inc., which was completed in January 2005. Including the one-time, non-cash IPR&D charge, the company reported an operating loss of $21.1 million and a net loss of $24.4 million, or ($1.34) per diluted share. Excluding the charge, operating income grew 37% to a record $9.1 million, from $6.7 million in the prior-year period; net income increased 36% to a record $5.9 million, from $4.3 million in the same period last year; and diluted earnings per share was $.32, compared with $.24 in the second quarter of fiscal 2004.

For the first six months of fiscal 2005, revenue was a record $29.8 million, an increase of 20% from $24.8 million in fiscal 2004. Including the one-time, non-cash IPR&D charge, the company reported an operating loss of $12.5 million and a net loss of $19.1 million, or ($1.07) per diluted share. Excluding the IPR&D charge, operating income grew 37% to a record $17.8 million, from $13.0 million in the prior-year period; net income increased 37% to a record $11.1 million, from $8.4 million in the same period last year; and diluted earnings per share was a record $.61, compared with $.47 in the first six months of fiscal 2004.

"We are pleased with the growth Cordis has achieved again this quarter with its CYPHER stent," said Bruce Barclay, President and COO. "Their reported CYPHER sales of $617 million for the March quarter is a record and reflects sequential growth of 10% from the December quarter. Additionally, we believe that the growing body of clinical data, which was enhanced at the American College of Cardiology conference in March, bodes very well for CYPHER's continued growth."

"Against this backdrop of strong sequential revenue growth from Cordis, our non-Cordis revenue has grown even faster and has exceeded Cordis revenue for the fourth consecutive quarter," continued Barclay. "We are greatly encouraged by the level of customer interest in the company's growing technology portfolio and are particularly excited about our future opportunities in ophthalmology, following our recent acquisition of InnoRx."

"After closing the acquisition of InnoRx in January, we have been actively integrating the company into our operations," commented Barclay. "We expect to begin human clinical trials for our drug-coated intravitreal implant in our fiscal third quarter. Interest in the acquired technology platforms remains very strong."

SurModics' pipeline remains strong. The Company signed six new licenses in the second quarter, bringing year-to-date licenses to 10 and demonstrating strong progress toward the company's stated goal of signing 12 new licenses in fiscal 2005. During the quarter, SurModics' customers introduced 2 new products, bringing the fiscal year-to-date total to 6, well on the way to the goal of 10 for fiscal year 2005. At March 31, a total of 82 coated products were on the market generating royalty revenue, compared with 72 in the prior-year period; the total number of licensed products not yet launched was 64, compared with 63 a year ago; and major non-licensed opportunities stood at 52, compared with 57 a year ago. In total, the company now has 116 potential commercial products in development with opportunities in each of the company's four focus markets - ophthalmology, cardiovascular, neurology and orthopedics.

"We are in excellent financial condition," said Phil Ankeny, CFO and Vice President of Business Development. "Our balance sheet remains strong, with a cash and investment balance of $56.7 million and no debt as of March 31. We are pleased with our continued progress putting the balance sheet to work. The three transactions we completed in the second quarter - our acquisition of InnoRx, our investment in OctoPlus and our license from Rutgers - position us well strategically."

Live Webcast

SurModics will host a Webcast at 5:00 p.m. ET (4:00 p.m. CT) today to discuss the quarterly results. To access the Webcast, go to the investor relations portion of the company's web site, www.surmodics.com, and click on the second quarter webcast icon. If you do not have access to the Internet and want to listen to the audio, dial 800-240-2430. A replay of the second quarter conference call, will be available by dialing 800-405-2236 and entering conference call ID 11027932. The audio replay will be available beginning at 6:00 p.m. CT on Wednesday, April 20, until 5:00 p.m. CT on Wednesday, April 27.

About SurModics, Inc.

SurModics, Inc., a leading provider of surface modification and drug delivery solutions, licenses its proprietary technologies to medical device, diagnostics, and biotechnology companies around the world. A significant portion of SurModics' revenue is generated through royalties on the sale of coated products. SurModics' Internet address is www.surmodics.com. The content of SurModics' web site is not part of this release or part of any filings the company makes with the SEC.

Safe Harbor for Forward Looking Statements

Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and SurModics intends that such forward looking statements be subject to the safe harbor created thereby. SurModics does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

                            SurModics, Inc.
                       Statements of Operations
                 (In thousands, except per share data)

                                 Three Months Ended  Six Months Ended
                                     March 31,          March 31,
                                 ------------------ ------------------
                                   2005     2004      2005     2004
                                 ------------------ ------------------
                                    (Unaudited)        (Unaudited)

                                           Restated           Restated
Revenue:
  Royalties and license fees      $12,268   $8,944   $22,359  $17,572
  Product sales                     2,321    2,803     4,321    5,403
  Research & development            1,116      991     3,094    1,850
                                 --------- -------- --------- --------
     Total revenue                 15,705   12,738    29,774   24,825

Operating expenses:
  Product                             730      752     1,349    1,488
  Research & development            3,890    3,140     7,246    6,411
  Sales & marketing                   307      588       569    1,006
  General & administrative          1,649    1,580     2,843    2,955
  Purchased In-Process R&D         30,277       --    30,277       --
                                 --------- -------- --------- --------
     Total operating expenses      36,853    6,060    42,284   11,860
                                 --------- -------- --------- --------
Income (loss) from operations     (21,148)   6,678   (12,510)  12,965

Investment income                     315      203       287      499
                                 --------- -------- --------- --------
Net income (loss) before income
 taxes                            (20,833)   6,881   (12,223)  13,464

Income tax provision               (3,538)  (2,576)   (6,911)  (5,048)

                                 --------- -------- --------- --------
Net income (loss)                ($24,371)  $4,305  ($19,134)  $8,416
                                 ========= ======== ========= ========

Basic net income (loss) per share  ($1.34)   $0.25    ($1.07)   $0.48
                                 ========= ======== ========= ========

Diluted net income (loss) per
 share                             ($1.34)   $0.24    ($1.07)   $0.47
                                 ========= ======== ========= ========

Weighted average shares
 outstanding
  Basic                            18,135   17,483    17,851   17,468
  Diluted                          18,135   17,775    17,851   17,774

Results previously reported have been restated to show the impact of
accounting for InnoRx under the equity method. Prior to completing the
acquisition of InnoRx in January 2005, the company accounted for its
investment in InnoRx under the cost method.



                           SurModics, Inc.
                   Comparative Analysis of Earnings
                (In thousands, except per share data)


                                 Three Months Ended  Six Months Ended
                                     March 31,          March 31,
                                 ------------------ ------------------
                                   2005     2004      2005     2004
                                 ------------------ ------------------
                                    (Unaudited)        (Unaudited)

                                           Restated           Restated
Income (loss) from operations
 (GAAP)                          ($21,148)  $6,678  ($12,510) $12,965

Add: Purchased In-Process R&D     $30,277       --   $30,277       --
Comparative income from
 operations                        $9,129   $6,678   $17,767  $12,965


Diluted net income (loss) per
 share (GAAP)                      ($1.34)   $0.24    ($1.07)   $0.47

Add: Net impact of Purchased
 In-Process R&D                     $1.66       --     $1.68       --
Comparative diluted net income
 per share                          $0.32    $0.24     $0.61    $0.47

Results previously reported have been restated to show the impact of
accounting for InnoRx under the equity method. Prior to completing the
acquisition of InnoRx in January 2005, the company accounted for its
investment in InnoRx under the cost method.

Certain information in the attached financial release may be
considered non-GAAP Financial Information as contemplated by SEC
Regulation G. Accordingly, we are providing the preceding table, which
reconciles results to their corresponding GAAP based operating results
presented under our Statement of Operations, in the accompanying press
release.

Management believes the presentation of these non-GAAP financial
results, in connection with the results of the fiscal quarter ended
March 31, 2005, provide useful information to investors regarding our
results of operations, as these non-GAAP financial measures allow
investors to better evaluate ongoing business performance and factors
that influenced performance during the period under report. Management
also uses these non-GAAP measures internally to monitor performance of
the business. These non-GAAP financial measures should be considered
in addition to, and not a substitute for, financial measures prepared
in accordance with GAAP.



                            SurModics, Inc.
                       Condensed Balance Sheets
                            (in thousands)

                                             March 31,   September 30,
                                               2005          2004
                                           ------------- -------------
Assets                                      (Unaudited)     Restated
------

Current assets:
  Cash & investments                             $8,843       $19,215
  Accounts receivable                            11,277         8,130
  Inventories                                       992         1,040
  Other current assets                            1,439         1,184
                                           ------------- -------------
    Total current assets                         22,551        29,569

Property & equipment, net                        15,155        15,738
Long-term investments                            47,832        44,088
Other assets                                     23,949        20,192

                                           ------------- -------------
  Total assets                                 $109,487      $109,587
                                           ============= =============

Liabilities & Stockholders' Equity
----------------------------------

Total current liabilities                        $4,570       $11,789

Other liabilities                                11,523         3,488

Total stockholders' equity                       93,394        94,310

                                           ------------- -------------
  Total liabilities & stockholders' equity     $109,487      $109,587
                                           ============= =============

Results previously reported have been restated to show the impact of
accounting for InnoRx under the equity method. Prior to completing the
acquisition of InnoRx in January 2005, the company accounted for its
investment in InnoRx under the cost method.

CONTACT: SurModics, Inc.
Phil Ankeny, 952-829-2700

SOURCE: SurModics, Inc.